Biosimilar infliximab: Additional Phase III data

Data from 396 patients with moderate to severe RA despite methotrexate therapy who were re-randomized at week 54 to either transition from Remicade infliximab to Flixabi (n=94) or remain on treatment with Flixabi (n=201) or Remicade (n=101) in a double-blind,

Read the full 406 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE